We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

134 hedge funds and large institutions have $828M invested in Revance Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 49 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

179% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 14

81% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 27

49% more capital invested

Capital invested by funds: $554M → $828M (+$274M)

23% more funds holding

Funds holding: 109 → 134 (+25)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

21% less call options, than puts

Call options by funds: $1.65M | Put options by funds: $2.08M

Holders
134
Holders Change
+25
Holders Change %
+22.94%
% of All Funds
2.64%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
39
Increased
49
Reduced
27
Closed
14
Calls
$1.65M
Puts
$2.08M
Net Calls
-$435K
Net Calls Change
-$228K

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$21.2M
2
DM
Deerfield Management
New York
+$14M
3
Capital International Investors
Capital International Investors
California
+$13M
4
PA
Perceptive Advisors
New York
+$12.7M
5
PC
Polar Capital
United Kingdom
+$11.6M

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$11.6M
2
SCM
Sio Capital Management
New York
-$3.38M
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.08M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$2.82M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$6.46M +$6.18M +398,362 New
PPA
27
Parametric Portfolio Associates
Washington
$5.46M +$1.27M +81,921 +32%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$5.32M -$11.6M -746,842 -69%
N
29
Nuveen
North Carolina
$5.3M +$300K +19,344 +6%
Charles Schwab
30
Charles Schwab
California
$4.37M +$376K +24,274 +10%
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$4.3M +$730K +47,044 +22%
RPAM
32
Rhenman & Partners Asset Management
Sweden
$4.06M +$1.18M +76,083 +44%
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$4.03M +$1.72M +111,016 +81%
PCM
34
Pinz Capital Management
New York
$3.64M +$3.47M +224,000 New
Ameriprise
35
Ameriprise
Minnesota
$3.55M +$1.09M +70,404 +48%
CS
36
Candriam SCA
Luxembourg
$3.49M -$341K -22,000 -9%
OCM
37
Osterweis Capital Management
California
$3.4M +$3.25M +209,780 New
Deutsche Bank
38
Deutsche Bank
Germany
$2.53M +$1.93M +124,438 +398%
MS
39
Maven Securities
Jersey
$2.36M +$2.27M +146,498 New
EGI
40
EAM Global Investors
California
$2.21M +$2.12M +136,443 New
SEI Investments
41
SEI Investments
Pennsylvania
$1.81M +$1.73M +111,451 New
Millennium Management
42
Millennium Management
New York
$1.77M +$1.69M +109,199 New
Goldman Sachs
43
Goldman Sachs
New York
$1.75M +$515K +33,193 +44%
KOCAA
44
Knights of Columbus Asset Advisors
Connecticut
$1.74M +$1.66M +106,963 New
EI
45
EAM Investors
California
$1.71M +$1.64M +105,429 New
Morgan Stanley
46
Morgan Stanley
New York
$1.46M +$962K +62,049 +223%
Swiss National Bank
47
Swiss National Bank
Switzerland
$1.44M +$242K +15,600 +21%
PAI
48
Palo Alto Investors
California
$1.44M +$1.37M +88,590 New
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.43M +$308K +19,865 +29%
SCM
50
Sio Capital Management
New York
$1.42M -$3.38M -217,964 -71%
1
2
3 4 5

RVNC Hedge Fund Activity: Q4 2019 in Review

134 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2019, worth a combined $828M — up 49% from $554M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new RVNC positions and 14 closed out — a net gain of 25 holders — while 49 added to existing stakes and 27 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $21.2M. The largest seller was Bank of New York Mellon, cutting an estimated $11.6M.

  • 134 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2019, up from 109 in Q3 2019.
  • Funds reported $828M of Revance Therapeutics, Inc. stock for Q4 2019, up 49% quarter-over-quarter.
  • 39 funds opened new Revance Therapeutics, Inc. positions in Q4 2019 and 14 closed out, a net change of +25 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2019 was JP Morgan Chase, an estimated $21.2M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2019 was Bank of New York Mellon, an estimated $11.6M sold.

Based on aggregated 13F filings for Q4 2019.